Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024)
Anbio Biotechnology (NNNN) posted Non-Current Assets of $387440.0 for Q4 2024, up 523.53% on a QoQ basis from $62137.0 in Q4 2023, and up 523.53% year-over-year from $62137.0 in Q1 2024.
Powered by 
Analysis
Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024) Analysis & Trends
Anbio Biotechnology has reported Non-Current Assets for 2 years, with the latest figure at $387440.0 in Q4 2024.
- On a quarterly basis, Non-Current Assets rose 523.53% year-over-year to $387440.0 in Q4 2024; TTM through Dec 2025 was $449577.0, a N/A change from a year earlier, with the FY2024 full-year figure at $387440.0, up 523.53% from the prior year.
- Non-Current Assets was $387440.0 for Q4 2024 at Anbio Biotechnology, up from $62137.0 in the prior quarter.
- The five-year high for Non-Current Assets was $387440.0 in Q4 2024, with the low at $62137.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 28.97 Bn | 27.09 Bn | 2.18 Bn | 26.75 Bn |
| 2 | Lantheus Holdings | 6.56 Bn | 5.97 Bn | 241.86 Mn | 1.39 Bn |
| 3 | Heartflow | 4.40 Bn | 4.03 Bn | 53.19 Mn | 120.49 Mn |
| 4 | Neogen | 2.83 Bn | 2.64 Bn | 107.80 Mn | 2.74 Bn |
| 5 | Butterfly Network | 1.88 Bn | 1.75 Bn | 23.29 Mn | 45.05 Mn |
| 6 | Ceribell | 931.50 Mn | 802.24 Mn | 25.94 Mn | 8.50 Mn |
| 7 | Varex Imaging | 779.32 Mn | 694.02 Mn | 76.70 Mn | 466.90 Mn |
| 8 | Anbio Biotechnology | 755.43 Mn | 743.53 Mn | - | - |
| 9 | QuidelOrtho | 725.35 Mn | 601.95 Mn | - | 4.34 Bn |
| 10 | Prenetics Global | 339.92 Mn | 280.78 Mn | 30.20 Mn | 5.98 Mn |